1. Габрусенко С.А., Селезнев Д.М., Наумов В.Г. Генетические аспекты гипертрофической кардиомиопатии (обзор литературы)//Практикующий врач. 2000. Т. 18. N 2. С. 2 - 5.

2. Шляхто Е.В. и др. Первичные кардиомиопатии, современное представление//Терапевтический архив. 2005. Т. 77. N 12. С. 77 - 83.

3. Gersh B.J. et al. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: Executive summary: A report of the American College of cardiology foundation/American heart association task force on practice guidelines//Circulation. 2011. Vol. 124, N 24. P. 2761 - 2796.

4. Elliott P. et al. 2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy: The task force for the diagnosis and management of hypertrophic cardiomyopathy of the European Society of Cardiology (ESC)//Eur. Heart J. 2014. Vol. 35, N 39. P. 2733 - 2779.

5. Alfares A.A. et al. Results of clinical genetic testing of 2,912 probands with hypertrophic cardiomyopathy: Expanded panels offer limited additional sensitivity//Genet. Med. 2015. Vol. 17, N 11. P. 880 - 888.

6. Coats C.J., Elliott P.M. Genetic biomarkers in hypertrophic cardiomyopathy//Biomark. Med. 2013. Vol. 7, N 4. P. 505 - 516.

7. Elliott P., McKenna W.J. Hypertrophic cardiomyopathy//Lancet. 2004. Vol. 363, N 9424. P. 1881 - 1891.

8. Kelly M.A. et al. Adaptation and validation of the ACMG/AMP variant classification framework for MYH7-associated inherited cardiomyopathies: Recommendations by ClinGen's Inherited Cardiomyopathy Expert Panel//Genet. Med. 2018. Vol. 20, N 3. P. 351 - 359.

9. Kokado H. et al. Clinical features of hypertrophic cardiomyopathy caused by a Lys183 deletion mutation in the cardiac troponin I gene//Circulation. 2000. Vol. 102, N 6. P. 663 - 669.

10. Kostareva A. et al. Deletion in TNNI3 gene is associated with restrictive cardiomyopathy//Int. J. Cardiol. 2009. Vol. 131, N 3. P. 410 - 412.

11. Maron B.J. Hypertrophic Cardiomyopathy: A Systematic Review//JAMA. 2002. Vol. 287, N 10. P. 1308 - 1320.

12. Maron B.J. et al. Moving Beyond the Sarcomere to Explain Heterogeneity in Hypertrophic Cardiomyopathy: JACC Review Topic of the Week//J. Am. Coll. Cardiol. 2019. Vol. 73, N 15. P. 1978 - 1986.

13. Mogensen J. et al. Frequency and Clinical Expression of Cardiac Troponin I Mutations in 748 Consecutive Families With Hypertrophic Cardiomyopathy//J. Am. Coll. Cardiol. 2004. Vol. 44. P. 2315 - 2325.

14. Селезнев Д.М. и др. Роль мутаций в гене тяжелой цепи сердечного бета-миозина в российской популяции больных с гипертрофической кардиомиопатией//Кардиология. 2005. Т. 45. N 4. С. 15 - 20.

15. Туральчук М.В., Новик Г.А., Гудкова А.Я. Особенности течения кардиомиопатий с рестриктивным фенотипом, обусловленных мутациями генов сердечного тропонина I и десмина, и алгоритмы их диагностики//Педиатрическая фармакология. 2011. Т. 8. N 4. С. 112 - 116.

16. Burton D. et al. Two mutations in troponin I that cause hypertrophic cardiomyopathy have contrasting effects on cardiac muscle contractility//Biochem. J. 2002. Vol. 362, N 2. P. 443 - 451.

17. Zhou N. et al. Whole-exome sequencing identifies rare compound heterozygous mutations in the MYBPC3 gene associated with severe familial hypertrophic cardiomyopathy//Eur. J. Med. Genet. 2018. Vol. 61, N 8. P. 434 - 441.

18. Charron P. et al. Accuracy of European diagnostic criteria for familial hypertrophic cardiomyopathy in a genotyped population//Int. J. Cardiol. 2003. Vol. 90, N 1. P. 33 - 38.

19. Lopes L.R. et al. Use of high-throughput targeted exome-sequencing to screen for copy number variation in hypertrophic cardiomyopathy//Eur. J. Med. Genet. 2015. Vol. 58, N 11. P. 611 - 616.

20. Brignole M. et al. 2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: The Task Force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association//Europace. 2013. Vol. 15, N 8. P. 1070 - 1118.

21. Hiemstra Y.L. et al. Development of and Progression of Overt Heart Failure in Nonobstructive Hypertrophic Cardiomyopathy//Am. J. Cardiol. 2018. Vol. 122, N 4. P. 656 - 662.

22. Ho C.Y. et al. The burden of early phenotypes and the influence of wall thickness in hypertrophic cardiomyopathy mutation carriers: Findings from the HCMNet study//JAMA Cardiol. 2017. Vol. 2, N 4. P. 419 - 428.

23. Hodatsu A. et al. Compound heterozygosity deteriorates phenotypes of hypertrophic cardiomyopathy with founder MYBPC3 mutation: Evidence from patients and zebrafish models//Am. J. Physiol. - Hear. Circ. Physiol. 2014. Vol. 307, N 11. P. H1594 - H1604.

24. Horimoto M. et al. Development of obstructive hypertrophic cardiomyopathy from nonobstructive hypertrophic cardiomyopathy//Am. J. Cardiol. 1998. Vol. 82, N 3. P. 403 - 405.

25. Ansari-Lari M.A., Ali S.Z. Fine-Needle Aspiration of Abdominal Fat Pad for Amyloid Detection: A Clinically Useful Test?//Diagn. Cytopathol. 2004. Vol. 30, N 3. P. 178 - 181.

26. Canepa M. et al. Comparison of clinical presentation, left ventricular morphology, hemodynamics, and exercise tolerance in obese versus nonobese patients with hypertrophic cardiomyopathy//Am. J. Cardiol. 2013. Vol. 112, N 8. P. 1182 - 1189.

27. Charron P. et al. Genetic counselling and testing in cardiomyopathies: A position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases//Eur. Heart J. 2010. Vol. 31, N 22. P. 2715 - 2728.

28. Finocchiaro G. et al. Impact of demographic features, lifestyle, and comorbidities on the clinical expression of hypertrophic cardiomyopathy//J. Am. Heart Assoc. 2017. Vol. 6, N 12. P. e007161.

29. Bos J.M., Ommen S.R., Ackerman M.J. Genetics of hypertrophic cardiomyopathy: one, two, or more diseases?//Curr. Opin. Cardiol. 2007. Vol. 22, N 3. P. 193 - 199.

30. Richards S. et al. Standards and guidelines for the interpretation of sequence variants: A joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology//Genet. Med. 2015. Vol. 17, N 5. P. 405 - 424.

31. Marian A.J., Braunwald E. Hypertrophic cardiomyopathy: Genetics, pathogenesis, clinical manifestations, diagnosis, and therapy//Circ. Res. 2017. Vol. 121, N 7. P. 749 - 770.

32. Бокерия Л.А. и др. Экспрессия генов матриксной металлопротеиназы-1 (ММР-1), тканевого ингибитора матриксных металлопротеиназ-1 (TIMP-1), коллагена I и III типов в миокарде больных идиопатической гипертрофической кардиомиопатией//Бюллетень НЦССХ им. А.Н. Бакулева РАМН. 2005. Т. 6. N 4. С. 35 - 42.

33. Гудкова А.Я. и др. Гипертрофическая кардиомиопатия. Клинико-морфологические сопоставления//Архив патологии. 2012. Т. 74. N 4. С. 8 - 11.

34. Гудкова А.Я. Характеристика течения обструктивной гипертрофической кардиомиопатии у взрослых (обзор литературы и результаты собственных исследований)//Артериальная гипертензия. 2008. Т. 14. N 2, Приложение 2. С. 39 - 49.

35. Гудкова А.Я., Шляхто Е.В. Клеточные механизмы гипертрофии миокарда при гипертрофической кардиомиопатии и эссенциальной артериальной гипертензии//Артериальная гипертензия. 2008. Т. 14. N 4. С. 364 - 380.

36. Shlyakhto E. V. et al. Cellular aspects of pathogenesis of hypertrophic cardiomyopathy: Role of cardiomyocyte polyploidy and activation of nuclear antigen of the proliferating cell in myocardium//Cell tissue biol. 2007. Vol. 1, N 6. P. 582 - 588.

37. Frustaci A., Russo M.A., Chimenti C. Diagnostic contribution of left ventricular endomyocardial biopsy in patients with clinical phenotype of hypertrophic cardiomyopathy//Hum. Pathol. 2013. Vol. 44, N 1. P. 133 - 141.

38. Leone O. et al. 2011 Consensus statement on endomyocardial biopsy from the Association for European Cardiovascular Pathology and the Society for Cardiovascular Pathology//Cardiovasc. Pathol. 2012. Vol. 21, N 4. P. 245 - 274.

39. Philipson D.J. et al. Emerging pharmacologic and structural therapies for hypertrophic cardiomyopathy//Heart Fail. Rev. 2017. Vol. 22, N 6. P. 879 - 888.

40. Roberts R., Sigwart U. Current concepts of the pathogenesis and treatment of hypertrophic cardiomyopathy//Circulation. 2005. Vol. 112, N 2. P. 293 - 296.

41. Varnava A.M. et al. Hypertrophic cardiomyopathy: The interrelation of disarray, fibrosis and small vessel disease//Heart. 2000. Vol. 84, N 5. P. 476 - 482.

42. Зайцев В.В. и др. Клиническое значение различных методов оценки миокардиального фиброза при гипертрофической кардиомиопатии//Кардиология. 2020. Т. 60. N 3. С. 44 - 50.

43. Arbustini E. et al. The MOGE(S) classification for a phenotype-genotype nomenclature of cardiomyopathy: Endorsed by the world heart federation//J. Am. Coll. Cardiol. 2013. Vol. 62, N 22. P. 2046 - 2072.

44. Barcia G. et al. Pitfalls in molecular diagnosis of Friedreich ataxia//Eur. J. Med. Genet. 2018. Vol. 61, N 8. P. 455 - 458.

45. Bokhari S. et al. 99mTc-pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses//Circ. Cardiovasc. Imaging. 2013. Vol. 6, N 2. P. 195 - 201.

46. Charron P. et al. Danon's disease as a cause of hypertrophic cardiomyopathy: A systematic survey//Heart. 2004. Vol. 90, N 8. P. 842 - 846.

47. Cook A., Giunti P. Friedreich's ataxia: Clinical features, pathogenesis and management//Br. Med. Bull. 2017. Vol. 124, N 1. P. 19 - 30.

48. D'souza A. et al. Localized insulin-derived amyloidosis: A potential pitfall in the diagnosis of systemic amyloidosis by fat aspirate//Am. J. Hematol. 2012. Vol. 87, N 11. P. E131 - 132.

49. Dubrey S.W., Hawkins P.N., Falk R.H. Amyloid diseases of the heart: Assessment, diagnosis, and referral//Heart. 2011. Vol. 97, N 1. P. 75 - 84.

50. Frustaci A. et al. Evolution of cardiac pathology in classic Fabry disease: Progressive cardiomyocyte enlargement leads to increased cell death and fibrosis, and correlates with severity of ventricular hypertrophy//Int. J. Cardiol. 2017. Vol. 248. P. 257 - 262.

51. Monserrat L. et al. Prevalence of Fabry Disease in a Cohort of 508 Unrelated Patients With Hypertrophic Cardiomyopathy//J. Am. Coll. Cardiol. 2007. Vol. 50, N 25. P. 2399 - 2403.

52. V., Said G. Familial amyloid polyneuropathy//Lancet Neurol. 2011. Vol. 10, N 12. P. 1086 - 1097.

53. Quarta C.C. et al. Defining the diagnosis in echocardiographically suspected senile systemic amyloidosis//JACC Cardiovasc. Imaging. 2012. Vol. 5, N 7. P. 755 - 758.

54. European Reference Networks in the Field of Rare Diseases: State of the Art and Future Directions. Third Report [Electronic resource]. 2008. URL: http://www.eucerd.eu/?post_type=document&p=1204.

55. Sado D.M. et al. Identification and assessment of anderson-fabry disease by cardiovascular magnetic resonance noncontrast myocardial T1 mapping//Circ. Cardiovasc. Imaging. 2013. Vol. 6, N 3. P. 392 - 398.

56. Tsai S.B. et al. Myocardial infarction with "clean coronaries" caused by amyloid light-chain AL amyloidosis: A case report and literature review//Amyloid. 2011. Vol. 18, N 3. P. 160 - 164.

57. Vogelsberg H. et al. Cardiovascular Magnetic Resonance in Clinically Suspected Cardiac Amyloidosis. Noninvasive Imaging Compared to Endomyocardial Biopsy//J. Am. Coll. Cardiol. 2008. Vol. 51, N 10. P. 1022 - 1030.

58. Wilkinson J.D. et al. Outcomes in children with Noonan syndrome and hypertrophic cardiomyopathy: A study from the Pediatric Cardiomyopathy Registry//Am. Heart J. 2012. Vol. 164, N 3. P. 442 - 448.

59. Yang Z., Vatta M. Danon disease as a cause of autophagic vacuolar myopathy//Congenit. Heart Dis. 2007. Vol. 2, N 6. P. 404 - 409.

60. Yang Z. et al. Danon Disease as an Underrecognized Cause of Hypertrophic Cardiomyopathy in Children//Circulation. 2005. Vol. 112, N 11. P. 1612 - 1617.

61. Ibrahim M. et al. Modern Management of Systolic Anterior Motion of the Mitral Valve//Eur J Cardiothorac Surg. 2012. Vol. 41. P. 60 - 70.

62. Deng L. et al. Numerical simulation study on systolic anterior motion of the mitral valve in hypertrophic obstructive cardiomyopathy//Int. J. Cardiol. 2018. Vol. 266. P. 167 - 173.

63. Manabe S. et al. Management of systolic anterior motion of the mitral valve: a mechanism-based approach//Gen. Thorac. Cardiovasc. Surg. 2018. Vol. 66, N 7. P. 379 - 389.

64. Ro R. et al. Vector flow mapping in obstructive hypertrophic cardiomyopathy to assess the relationship of early systolic left ventricular flow and the mitral valve//J. Am. Coll. Cardiol. 2014. Vol. 64, N 19. P. 1984 - 1995.

65. Hymel B.J., Townsley M.M. Echocardiographic assessment of systolic anterior motion of the mitral valve//Anesth. Analg. 2014. Vol. 118, N 6. P. 1197 - 1201.

66. Sherrid M. V. et al. Systolic anterior motion begins at low left ventricular outflow tract velocity in obstructive hypertrophic cardiomyopathy//J. Am. Coll. Cardiol. 2000. Vol. 36, N 4. P. 1344 - 1354.

67. Silbiger J.J. Abnormalities of the Mitral Apparatus in Hypertrophic Cardiomyopathy: Echocardiographic, Pathophysiologic, and Surgical Insights//J. Am. Soc. Echocardiogr. 2016. Vol. 29, N 7. P. 622 - 639.

68. Shah J.S. et al. Prevalence of exercise-induced left ventricular outflow tract obstruction in symptomatic patients with non-obstructive hypertrophic cardiomyopathy//Heart. 2008. Vol. 94, N 10. P. 1288 - 1294.

69. Geske J.B. et al. Variability of left ventricular outflow tract gradient during cardiac catheterization in patients with hypertrophic cardiomyopathy//JACC Cardiovasc. Interv. 2011. Vol. 4, N 6. P. 704 - 709.

70. Efthimiadis G.K. et al. Clinical characteristics and natural history of hypertrophic cardiomyopathy with midventricular obstruction//Circ. J. 2013. Vol. 77, N 9. P. 2366 - 2374.

71. Minami Y. et al. Clinical implications of midventricular obstruction in patients with hypertrophic cardiomyopathy//J. Am. Coll. Cardiol. 2011. Vol. 57, N 23. P. 2346 - 2355.

72. Yan L.R. et al. Clinical characteristics and prognosis of 60 patients with midventricular obstructive hypertrophic cardiomyopathy//J. Cardiovasc. Med. 2015. Vol. 16, N 11. P. 751 - 760.

73. Hang D. et al. Combined transaortic and transapical approach to septal myectomy in patients with complex hypertrophic cardiomyopathy//J. Thorac. Cardiovasc. Surg. 2018. Vol. 155, N 5. P. 2096 - 2102.

74. Pacheco Claudio C. et al. Why names matter for women: MINOCA/INOCA (myocardial infarction/ischemia and no obstructive coronary artery disease)//Clin. Cardiol. 2018. Vol. 41, N 2. P. 185 - 193.

75. Аверкина Н.В. и др. Оценка перфузии миокарда у больных с гипертрофической кардиомиопатией в сопоставлении с клиническими и эхокардиографическими данными//Терапевтический архив. 2003. Т. 75. N 4. С. 20 - 25.

76. Аверков О.В. и др. Дифференцированный подход в диагностике, формулировке диагноза, ведении больных и статистическом учете инфаркта миокарда 2 типа (согласованная позиция)//Российский кардиологический журнал. 2019. Т. 24. N 6. С. 7 - 21.

77. Каплунова В.Ю. и др. Гипертрофическая кардиомиопатия и ишемическая болезнь сердца. Варианты сочетанной патологии//Кардиология. 2017. Т. 57. N 12. С. 16 - 24.

78. Костин С.И. Морфологические и морфометрические особенности гипертрофической кардиомиопатии//Архив патологии. 1989. Т. 51. N 1. С. 47 - 52.

79. Мухарлямов Н. Кардиомиопатии. Москва, 1990. 283 с. с.

80. Aletras A.H. et al. Heterogeneity of intramural function in hypertrophic cardiomyopathy mechanistic insights from MRI late gadolinium enhancement and high-resolution displacement encoding with stimulated echoes strain maps//Circ. Cardiovasc. Imaging. 2011. Vol. 4, N 4. P. 425 - 434.

81. Camici P.G., Olivotto I., Rimoldi O.E. The coronary circulation and blood flow in left ventricular hypertrophy//J. Mol. Cell. Cardiol. 2012. Vol. 52, N 4. P. 857 - 864.

82. Einarsen E. et al. Comparison of Frequency of Ischemic Cardiovascular Events in Patients With Aortic Stenosis With Versus Without Asymmetric Septal Hypertrophy (from the SEAS Trial)//Am. J. Cardiol. 2017. Vol. 119, N 7. P. 1082 - 1087.

83. A. et al. Histopathological comparison of intramural coronary artery remodeling and myocardial fibrosis in obstructive versus end-stage hypertrophic cardiomyopathy//Int. J. Cardiol. 2019. Vol. 291. P. 77 - 82.

84. Kwon D.H. et al. Cardiac Magnetic Resonance Detection of Myocardial Scarring in Hypertrophic Cardiomyopathy. Correlation With Histopathology and Prevalence of Ventricular Tachycardia//J. Am. Coll. Cardiol. 2009. Vol. 54, N 3. P. 242 - 249.

85. Maron M.S. et al. The Case for Myocardial Ischemia in Hypertrophic Cardiomyopathy//J. Am. Coll. Cardiol. 2009. Vol. 54, N 9. P. 866 - 875.

86. Mundhenke M., Schwartzkopff B., Strauer B.E. Structural analysis of arteriolar and myocardial remodelling in the subendocardial region of patients with hypertensive heart disease and hypertrophic cardiomyopathy//Virchows Arch. 1997. Vol. 431, N 4. P. 265 - 273.

87. Nakamura T. et al. Increased plasma brain natriuretic peptide level as a guide for silent myocardial ischemia in patients with non-obstructive hypertrophic cardiomyopathy//J. Am. Coll. Cardiol. 2002. Vol. 39, N 10. P. 1657 - 1663.

88. Raphael C.E. et al. Mechanisms of Myocardial Ischemia in Hypertrophic Cardiomyopathy: Insights From Wave Intensity Analysis and Magnetic Resonance//J. Am. Coll. Cardiol. 2016. Vol. 68, N 15. P. 1651 - 1660.

89. R. et al. Myocardial blood flow and left ventricular functional reserve in hypertrophic cardiomyopathy: a 13NH3 gated PET study//Eur. J. Nucl. Med. Mol. Imaging. 2017. Vol. 44, N 5. P. 866 - 875.

90. Shin Y.J. et al. Clinical significance of evaluating coronary atherosclerosis in adult patients with hypertrophic cardiomyopathy who have chest pain//Eur. Radiol. 2019. Vol. 29, N 9. P. 4593 - 4602.

91. Liu W., Sun D., Yang J. Diastolic Dysfunction of Hypertrophic Cardiomyopathy Genotype-Positive Subjects Without Hypertrophy Is Detected by Tissue Doppler Imaging: A Systematic Review and Meta-analysis: A//J. Ultrasound Med. 2017. Vol. 36, N 10. P. 2093 - 2103.

92. Covella M. et al. Mechanism of Progressive Heart Failure and Significance of Pulmonary Hypertension in Obstructive Hypertrophic Cardiomyopathy//Circ. Hear. Fail. 2017. Vol. 10, N 4. P. e003689.

93. Germans T. et al. How do hypertrophic cardiomyopathy mutations affect myocardial function in carriers with normal wall thickness? Assessment with cardiovascular magnetic resonance//J. Cardiovasc. Magn. Reson. 2010. Vol. 12, N 1. P. 13.

94. Huang X. et al. Assessment of left ventricular systolic and diastolic abnormalities in patients with hypertrophic cardiomyopathy using real-time three-dimensional echocardiography and two-dimensional speckle tracking imaging//Cardiovasc. Ultrasound. 2018. Vol. 16, N 1. P. 23.

95. Matsumura Y. et al. Left ventricular diastolic function assessed using Doppler tissue imaging in patients with hypertrophic cardiomyopathy: Relation to symptoms and exercise capacity//Heart. 2002. Vol. 87, N 3. P. 247 - 251.

96. Бокерия Л.А., Борисов К.В., Синев А.Ф. Улучшение диастолической функции левого и правого желудочков сердца после хирургической коррекции гипертрофической обструктивной кардиомиопатии при помощи оригинального способа//Грудная и сердечно-сосудистая хирургия. 1999. Т. 4. С. 4 - 10.

97. Harris K.M. et al. Prevalence, clinical profile, and significance of left ventricular remodeling in the end-stage phase of hypertrophic cardiomyopathy//Circulation. 2006. Vol. 114, N 3. P. 216 - 225.

98. Biagini E. et al. Prognostic Implications of the Doppler Restrictive Filling Pattern in Hypertrophic Cardiomyopathy//Am. J. Cardiol. 2009. Vol. 104, N 12. P. 1727 - 1731.

99. Bravo P.E. et al. Late gadolinium enhancement confined to the right ventricular insertion points in hypertrophic cardiomyopathy: An intermediate stage phenotype?//Eur. Heart J. Cardiovasc. Imaging. 2016. Vol. 17, N 3. P. 293 - 300.

100. A. et al. Comparison of prevalence, clinical course, and pathological findings of left ventricular systolic impairment versus normal systolic function in patients with hypertrophic cardiomyopathy//Am. J. Cardiol. 2011. Vol. 108, N 4. P. 548 - 555.

101. Melacini P. et al. Clinicopathological profiles of progressive heart failure in hypertrophic cardiomyopathy//Eur. Heart J. 2010. Vol. 31, N 17. P. 2111 - 2123.

102. Maron M.S. et al. Right Ventricular Involvement in Hypertrophic Cardiomyopathy//Am. J. Cardiol. 2007. Vol. 100, N 8. P. 1293 - 1298.

103. Falcone D.M., Moore D., Lambert E.C. Idiopathic hypertrophic cardiomyopathy involving the right ventricle.//Am. J. Cardiol. 1967. Vol. 19, N 5. P. 735 - 740.

104. Shimizu M. et al. Echocardiographic assessment of right ventricular obstruction in hypertrophic cardiomyopathy//Circ. J. 2003. Vol. 67, N 10. P. 855 - 860.

105. Бокерия Л.А., Борисов К.В. Обструктивная гипертрофическая кардиомиопатия: методы хирургической коррекции//Грудная и сердечно-сосудистая хирургия. 1997. Т. 1. С. 61 - 65.

106. Бокерия Л.А. и др. Результаты медикаментозного и хирургического лечения гипертрофической кардиомиопатии с обструкцией выводных отделов левого и правого желудочков сердца//Грудная и сердечно-сосудистая хирургия. 2004. N 2. С. 4 - 9.

107. Бокерия Л.А. и др. Хирургическая коррекция ранее неоперабельных форм гипертрофической обструктивной кардиомиопатии//Грудная и сердечно-сосудистая хирургия. 1999. Т. 6. С. 130 - 136.

108. Pagourelias E.D. et al. Prognostic Value of Right Ventricular Diastolic Function Indices in Hypertrophic Cardiomyopathy//Eur. J. Echocardiogr. 2011. Vol. 12, N 11. P. 809 - 817.

109. Shah J.P. et al. Prevalence and Prognostic Significance of Right Ventricular Dysfunction in Patients With Hypertrophic Cardiomyopathy//Am. J. Cardiol. 2018. Vol. 122, N 11. P. 1932 - 1938.

110. Кактурский Л. Внезапная смерть (клиническая морфология). Москва, 2000. 126 с. с.

111. Ревишвили А.Ш. и др. Клинические рекомендации по проведению электрофизиологических исследований, катетерной абляции и применению имплантируемых антиаритмических устройств. Москва, 2017. 701 с. с.

112. Adabag A.S. et al. Spectrum and prognostic significance of arrhythmias on ambulatory Holter electrocardiogram in hypertrophic cardiomyopathy//J. Am. Coll. Cardiol. 2005. Vol. 45, N 5. P. 697 - 704.

113. Zipes D.P. et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death//Europace. 2006. Vol. 8, N 9. P. 746 - 837.

114. Czosek R.J. et al. Arrhythmic Burden and Ambulatory Monitoring of Pediatric Patients with Cardiomyopathy.//Pacing Clin. Electrophysiol. 2016. Vol. 39, N 5. P. 443 - 451.

115. Desai M.Y., Mentias A. Risk stratification in hypertrophic cardiomyopathy//Aging (Albany. NY). 2019. Vol. 11, N 6. P. 1617 - 1618.

116. Elliott P.M. et al. Sudden death in hypertrophic cardiomyopathy: Identification of high risk patients//J. Am. Coll. Cardiol. 2000. Vol. 36, N 7. P. 2212 - 2218.

117. Goyal V., Jassal D.S., Dhalla N.S. Pathophysiology and prevention of sudden cardiac death//Can. J. Physiol. Pharmacol. 2015. Vol. 94, N 3. P. 237 - 244.

118. Marrakchi S. et al. Risk stratification in hypertrophic cardiomyopathy//Herz. 2020. Vol. 45, N 1. P. 50 - 64.

119. Weissler-Snir A. et al. Prevention of Sudden Death in Hypertrophic Cardiomyopathy: Bridging the Gaps in Knowledge//Eur Hear. J. 2017. Vol. 38, N 22. P. 1728 - 1737.

120. Weissler-Snir A. et al. Usefulness of 14-Day Holter for Detection of Nonsustained Ventricular Tachycardia in Patients With Hypertrophic Cardiomyopathy//Am. J. Cardiol. 2016. Vol. 118, N 8. P. 1258 - 1263.

121. Goff Z.D., Calkins H. Sudden death related cardiomyopathies - Hypertrophic cardiomyopathy//Prog. Cardiovasc. Dis. 2019. Vol. 62, N 3. P. 212 - 216.

122. Bois J.P. et al. Relation between temperature extremes and symptom exacerbation in patients with hypertrophic cardiomyopathy//Am. J. Cardiol. 2016. Vol. 117, N 6. P. 961 - 965.

123. Haghjoo M. et al. Predictors of syncope in patients with hypertrophic cardiomyopathy//PACE - Pacing Clin. Electrophysiol. 2009. Vol. 32, N 5. P. 642 - 647.

124. H. et al. Syncope in hypertrophic (obstructive) cardiomyopathy//Herzschrittmachertherapie und Elektrophysiologie. 2018. Vol. 29, N 2. P. 178 - 182.

125. Williams L., Frenneaux M. Syncope in Hypertrophic Cardiomyopathy: Mechanisms and Consequences for Treatment//Europace. 2007. Vol. 9, N 9. P. 817 - 822.

126. Farhad H. et al. Left Atrial structure and function in hypertrophic cardiomyopathy sarcomere mutation carriers with and without left ventricular hypertrophy//J. Cardiovasc. Magn. Reson. 2017. Vol. 19, N 1. P. 107.

127. Burstein B., Nattel S. Atrial Fibrosis: Mechanisms and Clinical Relevance in Atrial Fibrillation//J. Am. Coll. Cardiol. 2008. Vol. 51, N 8. P. 802 - 809.

128. Philipson D.J., Rader F., Siegel R.J. Risk factors for atrial fibrillation in hypertrophic cardiomyopathy//Eur. J. Prev. Cardiol. 2019. P. doi: 10.1177/2047487319828474. Epub ahead of print.

129. Garg L. et al. Atrial fibrillation in hypertrophic cardiomyopathy: prevalence, clinical impact, and management//Heart Fail. Rev. 2019. Vol. 24, N 2. P. 189 - 197.

130. Killu A.M. et al. Cardiac Resynchronization Therapy in Patients With End-Stage Hypertrophic Cardiomyopathy//Europace. 2018. Vol. 20, N 1. P. 82 - 88.

131. Kirchhof P. et al. 2016 ESC Guidelines for the Management of Atrial Fibrillation Developed in Collaboration With EACTS//Eur. Heart J. 2016. Vol. 37. P. 2893 - 2962.

132. Maron B.J. et al. Clinical Spectrum and Management of Heart Failure in Hypertrophic Cardiomyopathy//JACC Hear. Fail. Elsevier Inc., 2018. Vol. 6, N 5. P. 353 - 363.

133. P.M. et al. Heart failure in cardiomyopathies: a position paper from the Heart Failure Association of the European Society of Cardiology//Eur. J. Heart Fail. 2019. Vol. 21, N 5. P. 553 - 576.

134. Maron B.J. et al. Epidemiology of Hypertrophic Cardiomyopathy-Related Death//Circulation. 2000. Vol. 102, N 8. P. 858 - 864.

135. Semsarian C. et al. New perspectives on the prevalence of hypertrophic cardiomyopathy//J. Am. Coll. Cardiol. 2015. Vol. 65, N 12. P. 1249 - 1254.

136. Amano Y. et al. MRI classification of asymmetric septal hypertrophic cardiomyopathy and its relation to the presence of risk factors//Int. J. Cardiovasc. Imaging. 2012. Vol. 28, N 8. P. 2019 - 2025.

137. Geske J.B., Ommen S.R., Gersh B.J. Hypertrophic Cardiomyopathy: Clinical Update//JACC Hear. Fail. 2018. Vol. 6, N 5. P. 364 - 375.

138. Дземешкевич С.Л. и др. Анатомические и морфологические признаки диффузно-генерализованной формы гипертрофической кардиомиопатии//Российский кардиологический журнал. 2015. Т. 5. N 121. С. 58 - 63.

139. Gudkova A. et al. Diagnostic challenge in desmin cardiomyopathy with transformation of clinical phenotypes//Pediatr. Cardiol. 2013. Vol. 34, N 2. P. 467 - 470.

140. Rowin E.J. et al. Interaction of Adverse Disease Related Pathways in Hypertrophic Cardiomyopathy//Am. J. Cardiol. 2017. Vol. 120, N 12. P. 2256 - 2264.

141. Габрусенко С.А. и др. Клинико-гемодинамический статус и сердечные натрийуретические пептиды в плазме больных гипертрофической кардиомиопатией//Кардиологический вестник (Бюллетень РКНПК). 2006. Т. 1. N 2. С. 25 - 31.

142. Стрельцова А.А., Гудкова А.Я., Костарева А.А. Фибрилляция предсердий при гипертрофической кардиомиопатии: современные аспекты эпидемиологии, факторов риска, патогенеза и фармакотерапии//Cons. Medicum. 2018. Т. 20. N 5. С. 34 - 39.

143. Стрельцова А.А. и др. Полиморфный вариант rs1739843 гена белка теплового шока 7 (HSPB7) и его связь с вариантами клинического течения и исходами у пациентов с гипертрофической кардиомиопатией (результаты 10-летнего наблюдения)//Российский кардиологический журнал. 2019. N 10. С. 7 - 15.

144. Binder J. et al. Echocardiography-guided genetic testing in hypertrophic cardiomyopathy: Septal morphological features predict the presence of myofilament mutations//Mayo Clin. Proc. 2006. Vol. 81, N 4. P. 459 - 467.

145. Elliott P., Spirito P. Prevention of hypertrophic cardiomyopathy-related deaths: Theory and practice//Heart. 2008. Vol. 94, N 10. P. 1269 - 1275.

146. Elliott P.M. et al. Historical trends in reported survival rates in patients with hypertrophic cardiomyopathy//Heart. 2006. Vol. 92, N 6. P. 785 - 791.

147. Kawai C. et al. Hypertrophic obstructive and non-obstructive cardiomyopathy in Japan. Diagnosis of the disease with special reference to endomyocardial catheter biopsy//Eur Hear. J. 1983. Vol. 4, N 1. P. 121 - 125.

148. Kitaoka H. et al. Hypertrophic Cardiomyopathy With Progression From Apical Hypertrophy to Asymmetrical Septal Hypertrophy: A Case Report//J. Cardiol. 2005. Vol. 45, N 4. P. 155 - 159.

149. Klues H.G., Schiffers A., Maron B.J. Phenotypic spectrum and patterns of left ventricular hypertrophy in hypertrophic cardiomyopathy: Morphologic observations and significance as assessed by two-dimensional echocardiography in 600 patients//J. Am. Coll. Cardiol. 1995. Vol. 26, N 7. P. 1699 - 1708.

150. Maron B.J. et al. Clinical profile of stroke in 900 patients with hypertrophic cardiomyopathy//J. Am. Coll. Cardiol. 2002. Vol. 39, N 2. P. 301 - 307.

151. Thaman R. et al. Progressive left ventricular remodeling in patients with hypertrophic cardiomyopathy and severe left ventricular hypertrophy//J. Am. Coll. Cardiol. 2004. Vol. 44, N 2. P. 398 - 405.

152. Lancellotti P. et al. The Clinical Use of Stress Echocardiography in Non-Ischaemic Heart Disease: Recommendations from the European Association of Cardiovascular Imaging and the American Society of Echocardiography.//J. Am. Soc. Echocardiogr. 2017. Vol. 30, N 2. P. 101 - 138.

153. Parato V.M. et al. Echocardiographic diagnosis of the different phenotypes of hypertrophic cardiomyopathy//Cardiovasc. Ultrasound. 2016. Vol. 14, N 1. P. 30.

154. Lambiase P.D. et al. Worldwide Experience With a Totally Subcutaneous Implantable Defibrillator: Early Results From the EFFORTLESS S-ICD Registry//Eur Hear. J. 2014. Vol. 35, N 25. P. 1657 - 1665.

155. Ponikowski P. et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution//Eur. J. Heart Fail. 2016. Vol. 18, N 8. P. 891 - 975.

156. Maron B.J. et al. American College of Cardiology/European Society of Cardiology Clinical Expert Consensus Document on Hypertrophic Cardiomyopathy: A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European S//Eur. Heart J. 2003. Vol. 24, N 21. P. 1965 - 1991.

157. Barrett M.J., Ayub B., Martinez M.W. Cardiac auscultation in sports medicine: Strategies to improve clinical care//Curr. Sports Med. Rep. 2012. Vol. 11, N 2. P. 78 - 84.

158. Cantwell J.D. Preparticipation physical evaluation: Getting to the heart of the matter//Med. Sci. Sports Exerc. 1998. Vol. 30, N 10. P. 341 - 344.

159. Efthimiadis G.K. et al. Prevalence and Clinical Outcomes of Incidentally Diagnosed Hypertrophic Cardiomyopathy//Am. J. Cardiol. 2010. Vol. 105, N 10. P. 1445 - 1450.

160. Harmon K.G., Zigman M., Drezner J.A. The effectiveness of screening history, physical exam, and ECG to detect potentially lethal cardiac disorders in athletes: A systematic review/meta-analysis//J. Electrocardiol. 2015. Vol. 48, N 3. P. 329 - 338.

161. Raviele A. et al. Management of Patients With Palpitations: A Position Paper From the European Heart Rhythm Association//Europace. 2011. Vol. 13, N 7. P. 920 - 934.

162. Attenhofer Jost C.H. et al. Echocardiography in the evaluation of systolic murmurs of unknown cause//Am. J. Med. 2000. Vol. 108, N 8. P. 614 - 620.

163. Rapezzi C. et al. Diagnostic work-up in cardiomyopathies: bridging the gap between clinical phenotypes and final diagnosis. A position statement from the ESC Working Group on Myocardial and Pericardial Diseases//Eur Hear. J. 2013. Vol. 34. P. 1448 - 1458.

164. Rapezzi C. et al. Disease profile and differential diagnosis of hereditary transthyretin-related amyloidosis with exclusively cardiac phenotype: an Italian perspective//Eur Hear. J. 2013. Vol. 34, N 7. P. 520 - 528.

165. Sarkozy A., Digilio M.C., Dallapiccola B. Leopard syndrome//Orphanet J. Rare Dis. 2008. Vol. 3, N 1. P. 13.

166. Scaglia F. et al. Clinical Spectrum, Morbidity, and Mortality in 113 Pediatric Patients with Mitochondrial Disease//Pediatrics. 2004. Vol. 114, N 4. P. 925 - 931.

167. Pagourelias E.D. et al. Efficacy of various "classic" echocardiographic and laboratory indices in distinguishing the "gray zone" between athlete's heart and hypertrophic cardiomyopathy: A pilot study//Echocardiography. 2013. Vol. 30, N 2. P. 131 - 139.

168. Coutu M. et al. Cardiac transplantation for hypertrophic cardiomyopathy: a valid therapeutic option.//J. Heart Lung Transplant. 2004. Vol. 23, N 4. P. 413 - 417.

169. Zhang C., Huang X., Li J. Light chain amyloidosis: Where are the light chains from and how they play their pathogenic role?//Blood Rev. 2017. Vol. 31, N 4. P. 261 - 270.

170. Ingles J. et al. Nonfamilial Hypertrophic Cardiomyopathy: Prevalence, Natural History, and Clinical Implications//Circ. Cardiovasc. Genet. 2017. Vol. 10, N 2. P. e001620.

171. Maron B.J., Pelliccia A., Spirito P. Cardiac disease in young trained athletes: Insights into methods for distinguishing athlete's heart from structural heart disease, with particular emphasis on hypertrophic cardiomyopathy//Circulation. 1995. Vol. 91, N 5. P. 1596 - 1601.

172. Young L. et al. Hypertrophic cardiomyopathy: A complex disease//Cleve. Clin. J. Med. 2018. Vol. 85, N 5. P. 399 - 411.

173. Efthimiadis G.K. et al. Hypertrophic cardiomyopathy in 2013: Current speculations and future perspectives//World J Cardiol. 2014. Vol. 6, N 2. P. 26 - 37.

174. Hershberger R.E. et al. Genetic Evaluation of Cardiomyopathy-A Heart Failure Society of America Practice Guideline//J. Card. Fail. 2018. Vol. 24, N 5. P. 281 - 302.

175. Efthimiadis G.K. et al. An Overview of Pharmacotherapy in Hypertrophic Cardiomyopathy: Current Speculations and Clinical Perspectives.//Rev. Cardiovasc. Med. 2016. Vol. 17, N 3 - 4. P. 115 - 123.

176. Fananapazir L. et al. Electrophysiologic abnormalities in patients with hypertrophic cardiomyopathy. A consecutive analysis in 155 patients//Circulation. 1989. Vol. 80, N 5. P. 1259 - 1268.

177. Kelly B.S., Mattu A., Brady W.J. Hypertrophic cardiomyopathy: electrocardiographic manifestations and other important considerations for the emergency physician//Am. J. Emerg. Med. 2007. Vol. 25, N 1. P. 72 - 79.

178. McLeod C.J. et al. Outcome of Patients With Hypertrophic Cardiomyopathy and a Normal Electrocardiogram//J. Am. Coll. Cardiol. 2009. Vol. 54, N 3. P. 229 - 233.

179. Wilke I. et al. High Incidence of De Novo and Subclinical Atrial Fibrillation in Patients With Hypertrophic Cardiomyopathy and Cardiac Rhythm Management Device//J. Cardiovasc. Electrophysiol. 2016. Vol. 27, N 7. P. 779 - 784.

180. Хирманов В.Н. и др. Электрокардиографические методы в диагностике, выборе метода и тактики лечения гипертрофической кардиомиопатии//Prog. Biomed. Res. 1997. Т. 2. N 1. С. 7 - 22.

181. O'Mahony C. et al. A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM Risk-SCD)//Eur Hear. J. 2014. Vol. 35, N 30. P. 2010 - 2020.

182. Wasfy M.M., Weiner R.B. Differentiating the athlete's heart from hypertrophic cardiomyopathy//Current Opinion in Cardiology. 2015. Vol. 30, N 5. P. 500 - 505.

183. Weigner M.J. et al. Risk for clinical thromboembolism associated with conversion to sinus rhythm in patients with atrial fibrillation lasting less than 48 hours//Ann. Intern. Med. 1997. Vol. 126, N 8. P. 615 - 620.

184. Guttmann O.P. et al. Atrial fibrillation and thromboembolism in patients with hypertrophic cardiomyopathy: Systematic review//Heart. 2014. Vol. 100, N 6. P. 465 - 472.

185. Brignole M. et al. Indications for the use of diagnostic implantable and external ECG loop recorders.//Europace. 2009. Vol. 11, N 5. P. 671 - 687.

186. Frangini P.A. et al. How revealing are insertable loop recorders in pediatrics?//Pacing Clin. Electrophysiol. 2008. Vol. 31, N 3. P. 338 - 343.

187. Solano A. et al. Incidence, diagnostic yield and safety of the implantable loop-recorder to detect the mechanism of syncope in patients with and without structural heart disease//Eur. Heart J. 2004. Vol. 25, N 13. P. 1116 - 1119.

188. Moon J.C.C. et al. The histologic basis of late gadolinium enhancement cardiovascular magnetic resonance in hypertrophic cardiomyopathy//J. Am. Coll. Cardiol. 2004. Vol. 43, N 12. P. 2260 - 2264.

189. O'Hanlon R. et al. Prognostic significance of myocardial fibrosis in hypertrophic cardiomyopathy//J. Am. Coll. Cardiol. 2010. Vol. 56, N 11. P. 867 - 874.

190. Pernat A., Pohar B., Horvat M. Heart conduction disturbances and cardiovascular collapse after disopyramide and low-dose metoprolol in a patient with hypertrophic obstructive cardiomyopathy//J. Electrocardiol. 1997. Vol. 30, N 4. P. 341 - 344.

191. Cerqueira M.D. et al. Standardized Myocardial Segmentation and Nomenclature for Tomographic Imaging of the Heart A Statement for Healthcare Professionals From the Cardiac Imaging Committee//Circulation. 2002. Vol. 105, N 4. P. 539 - 542.

192. Flachskampf F. et al. Recommendations for Transoesophageal Echocardiography: Update 2010//Eur. J. Echocardiogr. 2010. Vol. 11, N 7. P. 557 - 576.

193. Lang R.M. et al. Recommendations for cardiac chamber quantification by echocardiography in adults: An update from the American society of echocardiography and the European association of cardiovascular imaging//Eur. Heart J. Cardiovasc. Imaging. 2015. Vol. 16, N 3. P. 233 - 271.

194. Mitchell C. et al. Guidelines for Performing a Comprehensive Transthoracic Echocardiographic Examination in Adults: Recommendations from the American Society of Echocardiography//J. Am. Soc. Echocardiogr. 2018. Vol. 32, N 1. P. 1 - 64.

195. Nagueh S.F. et al. Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography//Eur. J. Echocardiogr. 2009. Vol. 10, N 2. P. 165 - 193.

196. Senior R. et al. Contrast echocardiography: evidence-based recommendations by European Association of Echocardiography//Eur J Echocardiogr. 2009. Vol. 10, N 2. P. 194 - 212.

197. Maron B.J. et al. Clinical course of hypertrophic cardiomyopathy with survival to advanced age//J. Am. Coll. Cardiol. 2003. Vol. 42, N 5. P. 882 - 888.

198. Maron B.J. et al. Nonobstructive Hypertrophic Cardiomyopathy Out of the Shadows: Known from the Beginning but Largely Ignored... Until Now//Am. J. Med. 2017. Vol. 130, N 2. P. 119 - 123.

199. Maron M.S. et al. Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction//Circulation. 2006. Vol. 114, N 21. P. 2232 - 2239.

200. Spirito P. et al. Risk of sudden death and outcome in patients with hypertrophic cardiomyopathy with benign presentation and without risk factors//Am. J. Cardiol. 2014. Vol. 113, N 9. P. 1550 - 1555.

201. Spirito P. et al. Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy//N. Engl. J. Med. 2000. Vol. 342, N 24. P. 1778 - 1785.

202. Belenkie I., MacDonald R.P.R., Smith E.R. Localized septal hypertrophy: Part of the spectrum of hypertrophic cardiomyopathy or an incidental echocardiographic finding?//Am. Heart J. 1988. Vol. 115, N 2. P. 385 - 390.

203. Gardin J. et al. Localized basal ventricular septal hypertrophy - prevalence, functional and clinical correlates in a population referred for echocardiography//Am J Noninvas Card. 1998. Vol. 6, N 1. P. 5 - 8.

204. Losi M.A. et al. Echocardiography in patients with hypertrophic cardiomyopathy: Usefulness of old and new techniques in the diagnosis and pathophysiological assessment//Cardiovasc. Ultrasound. 2010. Vol. 8, N 1. P. 7.

205. Alvares R.F., Goodwin J.F. Non-invasive assessment of diastolic function in hypertrophic cardiomyopathy on and off beta adrenergic blocking drugs//Br. Heart J. 1982. Vol. 48, N 3. P. 204 - 212.

206. Dimitrow P.P. et al. Left ventricular outflow tract gradient provoked by upright position or exercise in treated patients with hypertrophic cardiomyopathy without obstruction at rest.//Echocardiography. 2009. Vol. 26, N 5. P. 513 - 520.

207. Elliott P. et al. Left ventricular outflow tract obstruction and sudden death in hypertrophic cardiomyopathy//Eur. Heart J. 2006. Vol. 27, N 24. P. 3073 - 3074.

208. Nistri S. et al. Timing and significance of exercise-induced left ventricular outflow tract pressure gradients in hypertrophic cardiomyopathy//Am. J. Cardiol. 2010. Vol. 106, N 9. P. 1301 - 1306.

209. Olivotto I. et al. Clinical utility and safety of exercise testing in patients with hypertrophic cardiomyopathy//G. Ital. Cardiol. 1999. Vol. 29. P. 11 - 19.

210. Sadoul N. et al. Prospective prognostic assessment of blood pressure response during exercise in patients with hypertrophic cardiomyopathy//Circulation. 1997. Vol. 96, N 9. P. 2987 - 2991.

211. Tower-Rader A. et al. A Comprehensive Review of Stress Testing in Hypertrophic Cardiomyopathy: Assessment of Functional Capacity, Identification of Prognostic Indicators, and Detection of Coronary Artery Disease//J. Am. Soc. Echocardiogr. 2017. Vol. 30, N 9. P. 829 - 844.

212. F. et al. The effect of dobutamine stress on left ventricular outflow tract gradients in hypertensive patients with basal septal hypertrophy//Angiology. 2004. Vol. 55, N 3. P. 295 - 301.

213. Mestres C.A. et al. Hypertrophic Obstructive Cardiomyopathy: What, When, Why, for Whom?//Eur J Cardiothorac Surg. 2018. Vol. 53, N 4. P. 700 - 707.

214. Mickelsen S. et al. Doppler evaluation of the descending aorta in patients with hypertrophic cardiomyopathy: Potential for assessing the functional significance of outflow tract gradients and for optimizing pacemaker function//J. Interv. Card. Electrophysiol. 2004. Vol. 11, N 1. P. 47 - 53.

215. Tezuka A. et al. Bisoprolol successfully improved the intraventricular pressure gradient in a patient with midventricular obstructive hypertrophic cardiomyopathy with an apex aneurysm due to apical myocardial damage//Intern. Med. 2019. Vol. 58, N 4. P. 535 - 539.

216. Cardim N. et al. Role of multimodality cardiac imaging in the management of patients with hypertrophic cardiomyopathy: An expert consensus of the European Association of Cardiovascular Imaging Endorsed by the Saudi Heart Association//Eur. Heart J. Cardiovasc. Imaging. 2015. Vol. 16, N 3. P. 280.

217. Kim M.S. et al. Left Ventricular Outflow Tract Obstruction in the Presence of Asymmetric Septal Hypertrophy and Accessory Mitral Valve Tissue Treated With Alcohol Septal Ablation//Eur. J. Echocardiogr. 2008. Vol. 9, N 5. P. 720 - 724.

218. Monakier D. et al. Usefulness of myocardial contrast echocardiographic quantification of risk area for predicting postprocedural complications in patients undergoing septal ethanol ablation for obstructive hypertrophic cardiomyopathy//Am. J. Cardiol. 2004. Vol. 94, N 12. P. 1515 - 1522.

219. Wallace E.L. et al. Septal perforator anatomy and variability of perfusion bed by myocardial contrast echocardiography: A study of hypertrophic cardiomyopathy patients undergoing alcohol septal ablation//J. Interv. Cardiol. 2013. Vol. 26, N 6. P. 604 - 612.

220. Grigg L.E. et al. Transesophageal Doppler echocardiography in obstructive hypertrophic cardiomyopathy: Clarification of pathophysiology and importance in intraoperative decision making//J. Am. Coll. Cardiol. 1992. Vol. 20, N 1. P. 42 - 52.

221. Marwick T.H. et al. Benefits of intraoperative echocardiography in the surgical management of hypertrophic cardiomyopathy//J. Am. Coll. Cardiol. 1992. Vol. 20, N 5. P. 1066 - 1072.

222. Oki T. et al. Transesophageal echocardiographic evaluation of mitral regurgitation in hypertrophic cardiomyopathy: Contributions of eccentric left ventricular hypertrophy and related abnormalities of the mitral complex//J. Am. Soc. Echocardiogr. 1995. Vol. 8, N 4. P. 503 - 510.

223. Yu E.H.C. et al. Mitral regurgitation in hypertrophic obstructive cardiomyopathy: Relationship to obstruction and relief with myectomy//J. Am. Coll. Cardiol. 2000. Vol. 36, N 7. P. 2219 - 2225.

224. McIntosh C.L. et al. Initial Results of Combined Anterior Mitral Leaflet Plication and Ventricular Septal Myotomy-Myectomy for Relief of Left Ventricular Outflow Tract Obstruction in Patients With Hypertrophic Cardiomyopathy//Circulation. 1992. Vol. 86, N 5. P. 60 - 67.

225. Green J.J. et al. Prognostic value of late gadolinium enhancement in clinical outcomes for hypertrophic cardiomyopathy//JACC Cardiovasc. Imaging. 2012. Vol. 5, N 4. P. 370 - 377.

226. Moon J.C.C. et al. Detection of apical hypertrophic cardiomyopathy by cardiovascular magnetic resonance in patients with non-diagnostic echocardiography//Heart. 2004. Vol. 90, N 6. P. 645 - 649.

227. Olivotto I. et al. Assessment and Significance of Left Ventricular Mass by Cardiovascular Magnetic Resonance in Hypertrophic Cardiomyopathy//J. Am. Coll. Cardiol. 2008. Vol. 52, N 7. P. 559 - 566.

228. Prinz C. et al. Myocardial Fibrosis Severity on Cardiac Magnetic Resonance Imaging Predicts Sustained Arrhythmic Events in Hypertrophic Cardiomyopathy//Can. J. Cardiol. 2013. Vol. 29, N 3. P. 358 - 363.

229. Rickers C. et al. Utility of cardiac magnetic resonance imaging in the diagnosis of hypertrophic cardiomyopathy//Circulation. 2005. Vol. 112, N 6. P. 855 - 861.

230. Rudolph A. et al. Noninvasive Detection of Fibrosis Applying Contrast-Enhanced Cardiac Magnetic Resonance in Different Forms of Left Ventricular Hypertrophy. Relation to Remodeling//J. Am. Coll. Cardiol. 2009. Vol. 53, N 3. P. 284 - 291.

231. Webb J. et al. The Emerging Role of Cardiac Magnetic Resonance Imaging in the Evaluation of Patients with HFpEF//Curr. Heart Fail. Rep. 2018. Vol. 15, N 1. P. 1 - 9.

232. Albano B.B.P. et al. Treating a Structural Heart Disease Using a Non-structural Approach: Role of Cardiac Pacing in Hypertrophic Cardiomyopathy//Cardiol. Res. 2017. Vol. 8, N 1. P. 20 - 25.

233. Puntmann V.O. et al. Left ventricular chamber dimensions and wall thickness by cardiovascular magnetic resonance: comparison with transthoracic echocardiography//Eur Hear. J Cardiovasc Imaging. 2013. Vol. 14. P. 240 - 246.

234. Falk R.H. Diagnosis and management of the cardiac amyloidoses//Circulation. 2005. Vol. 112, N 13. P. 2047 - 2060.

235. Gillmore J.D. et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis//Circulation. 2016. Vol. 133, N 24. P. 2404 - 2412.

236. Syed I.S. et al. Role of Cardiac Magnetic Resonance Imaging in the Detection of Cardiac Amyloidosis//JACC Cardiovasc. Imaging. 2010. Vol. 3, N 2. P. 155 - 164.

237. Todiere G. et al. Progression of myocardial fibrosis assessed with cardiac magnetic resonance in hypertrophic cardiomyopathy//J. Am. Coll. Cardiol. 2012. Vol. 60, N 10. P. 922 - 929.

238. O'Hanlon R., Assomull R.G., Prasad S.K. Use of cardiovascular magnetic resonance for diagnosis and management in hypertrophic cardiomyopathy//Curr. Cardiol. Rep. 2007. Vol. 9, N 1. P. 51 - 56.

239. Patel P. et al. Left ventricular outflow tract obstruction in hypertrophic cardiomyopathy patients without severe septal hypertrophy: Implications of mitral valve and papillary muscle abnormalities assessed using cardiac magnetic resonance and echocardiography//Circ. Cardiovasc. Imaging. 2015. Vol. 8, N 7. P. e003132.

240. Gruner C. et al. Significance of left ventricular apical-basal muscle bundle identified by cardiovascular magnetic resonance imaging in patients with hypertrophic cardiomyopathy//Eur. Heart J. 2014. Vol. 35, N 39. P. 2706 - 2713.

241. Brouwer W.P. et al. Multiple myocardial crypts on modified long-axis view are a specific finding in pre-hypertrophic HCM mutation carriers//Eur Hear. J Cardiovasc Imaging. 2012. Vol. 13, N 4. P. 292 - 297.

242. Schroeder S. et al. Cardiac Computed Tomography: Indications, Applications, Limitations, and Training Requirements: Report of a Writing Group Deployed by the Working Group Nuclear Cardiology and Cardiac CT of the European Society of Cardiology and the European Council of Nuc//Eur Hear. J. 2008. Vol. 29, N 4. P. 531 - 556.

243. Esposito A. et al. Multidetector computed tomography for coronary stents imaging: High-voltage (140-KVP) prospective ecg-triggered versus standard-voltage (120-kvp) retrospective ecg-gated helical scanning//J. Comput. Assist. Tomogr. 2013. Vol. 37, N 3. P. 395 - 401.

244. Shiozaki A.A. et al. Myocardial fibrosis detected by cardiac CT predicts ventricular fibrillation/ventricular tachycardia events in patients with hypertrophic cardiomyopathy//J. Cardiovasc. Comput. Tomogr. 2013. Vol. 7, N 3. P. 173 - 181.

245. Rapezzi C. et al. Usefulness and limitations of 99mTc-3, 3-diphosphono-1, 2-propanodicarboxylic acid scintigraphy in the aetiological diagnosis of amyloidotic cardiomyopathy//Eur. J. Nucl. Med. Mol. Imaging. 2011. Vol. 38, N 3. P. 470 - 478.

246. Rapezzi C. et al. Role of 99mTc-DPD scintigraphy in diagnosis and prognosis of hereditary transthyretin-related cardiac amyloidosis//JACC Cardiovasc. Imaging. 2011. Vol. 4, N 6. P. 659 - 670.

247. Katayama M. et al. Left ventricular septal hypertrophy in elderly patients with aortic stenosis//J. Ultrasound Med. 2017. Vol. 37, N 1. P. 217 - 224.

248. Mitsutake R. et al. Usefulness of multi-detector row computed tomography for the management of percutaneous transluminal septal myocardial ablation in patient with hypertrophic obstructive cardiomyopathy//Int. J. Cardiol. 2008. Vol. 129, N 2. P. 61 - 63.

249. Scalone G., Niccoli G., Crea F. Editor's Choice-Pathophysiology, diagnosis and management of MINOCA: an update//Eur. Hear. journal. Acute Cardiovasc. care. 2019. Vol. 8, N 1. P. 54 - 62.

250. Okayama S. et al. Role of cardiac computed tomography in planning and evaluating percutaneous transluminal septal myocardial ablation for hypertrophic obstructive cardiomyopathy//J. Cardiovasc. Comput. Tomogr. 2010. Vol. 4, N 1. P. 62 - 65.

251. Villa A.D.M. et al. Microvascular ischemia in hypertrophic cardiomyopathy: New insights from high-resolution combined quantification of perfusion and late gadolinium enhancement//J. Cardiovasc. Magn. Reson. 2016. Vol. 18, N 4. P. doi:10.1186/s12968-016-0223-8. Epub ahead of print.

252. Chen J.M. et al. Reevaluating the significance of pulmonary hypertension before cardiac transplantation: Determination of optimal thresholds and quantification of the effect of reversibility on perioperative mortality//J. Thorac. Cardiovasc. Surg. 1997. Vol. 114, N 4. P. 627 - 634.

253. Kato T.S. et al. Cardiac transplantation in patients with hypertrophic cardiomyopathy//Am. J. Cardiol. 2012. Vol. 110, N 4. P. 568 - 574.

254. B. et al. High and low pulmonary vascular resistance in heart transplant candidates. A 5-year follow-up after heart transplantation shows continuous reduction in resistance and no difference in complication rate//Eur. Heart J. 1999. Vol. 20, N 2. P. 148 - 156.

255. Maron M.S. et al. Survival after cardiac transplantation in patients with hypertrophic cardiomyopathy//Circ. Hear. Fail. 2010. Vol. 3, N 5. P. 574 - 579.

256. Mehra M.R. et al. Listing Criteria for Heart Transplantation: International Society for Heart and Lung Transplantation Guidelines for the Care of Cardiac Transplant Candidates-2006//J. Hear. Lung Transplant. 2006. Vol. 25, N 9. P. 1024 - 1042.

257. Torres M.F., Perez-Villa F. Heart transplantation in patients with hypertrophic cardiomyopathy//Glob. Cardiol. Sci. Pract. 2018. Vol. 2018, N 3. P. 32.

258. C. et al. ACC/AHA/ESC Guidelines for the Management of Patients with Supraventricular Arrhythmias - Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology//J. Am. Coll. Cardiol. 2003. Vol. 42, N 8. P. 1493 - 1531.

259. Бокерия Л.А., Берсенева М.И., Маленков Д.А. Аритмогенные осложнения гипертрофической кардиомиопатии//Анналы аритмологии. 2010. Т. 7. N 3. С. 62 - 69.

260. Muresan L. et al. Recommendations for the use of electrophysiological study: Update 2018//Hell. J. Cardiol. 2019. Vol. 60, N 2. P. 82 - 100.

261. Wang W. et al. Prognostic Implications of Nonsustained Ventricular Tachycardia in High-Risk Patients With Hypertrophic Cardiomyopathy//Circ. Arrhythm. Electrophysiol. 2017. Vol. 10, N 3. P. e004604.

262. Inada K. et al. Substrate characterization and catheter ablation for monomorphic ventricular tachycardia in patients with apical hypertrophic cardiomyopathy//J. Cardiovasc. Electrophysiol. 2011. Vol. 22, N 1. P. 41 - 48.

263. Lim K.K., Maron B.J., Knight B.P. Successful catheter ablation of hemodynamically unstable monomorphic ventricular tachycardia in a patient with hypertrophic cardiomyopathy and apical aneurysm//J. Cardiovasc. Electrophysiol. 2009. Vol. 20, N 4. P. 445 - 447.

264. Refaat M.M., Hotait M., Tseng Z.H. Utility of the exercise electrocardiogram testing in sudden cardiac death risk stratification//Ann. Noninvasive Electrocardiol. 2014. Vol. 19, N 4. P. 311 - 318.

265. Yi G. et al. Can the Assessment of Dynamic QT Dispersion on Exercise Electrocardiogram Predict Sudden Cardiac Death in Hypertrophic Cardiomyopathy?//Pacing Clin. Electrophysiol. 2000. Vol. 23, N 11Pt2. P. 1953 - 1956.

266. Nistri S. et al. blockers for prevention of exercise-induced left ventricular outflow tract obstruction in patients with hypertrophic cardiomyopathy//Am. J. Cardiol. 2012. Vol. 110, N 5. P. 715 - 719.

267. Rowin E.J. et al. Role of Exercise Testing in Hypertrophic Cardiomyopathy//JACC Cardiovasc. Imaging. 2017. Vol. 10, N 11. P. 1374 - 1386.

268. Mancini D.M. et al. Value of peak exercise oxygen consumption for optimal timing of cardiac transplantation in ambulatory patients with heart failure//Circulation. 1991. Vol. 83, N 3. P. 778 - 786.

269. Sharma S. et al. Utility of cardiopulmonary exercise in the assessment of clinical determinants of functional capacity in hypertrophic cardiomyopathy//Am. J. Cardiol. 2000. Vol. 86, N 2. P. 162 - 168.

270. Колоскова Н.Н., Шаталов К.В., Бокерия Л.А. Определение пикового потребления кислорода: клиническое использование и перспективы//Креативная кардиология. 2014. Т. 2. С. 20 - 28.

271. Coats C.J. et al. Cardiopulmonary Exercise Testing and Prognosis in Hypertrophic Cardiomyopathy//Circ. Hear. Fail. 2015. Vol. 8, N 6. P. 1022 - 1031.

272. Arena R. et al. Ventilatory efficiency and resting hemodynamics in hypertrophic cardiomyopathy//Med. Sci. Sports Exerc. 2008. Vol. 40, N 5. P. 799 - 805.

273. Olivotto I. et al. Prognostic value of systemic blood pressure response during exercise in a community-based patient population with hypertrophic cardiomyopathy//J. Am. Coll. Cardiol. 1999. Vol. 33, N 7. P. 2044 - 2051.

274. Diodati J.G. et al. Predictors of exercise benefit after operative relief of left ventricular outflow obstruction by the myotomy-myectomy procedure in hypertrophic cardiomyopathy//Am. J. Cardiol. 1992. Vol. 69, N 19. P. 1617 - 1622.

275. Bennett M.K. et al. Evaluation of the role of endomyocardial biopsy in 851 patients with unexplained heart failure from 2000 - 2009//Circ. Hear. Fail. 2013. Vol. 6, N 4. P. 676 - 684.

276. S.O. et al. Immunohistochemistry in the classification of systemic forms of amyloidosis: A systematic investigation of 117 patients//Blood. 2012. Vol. 119, N 2. P. 488 - 493.

277. Quarta C.C. et al. Diagnostic Sensitivity of Abdominal Fat Aspiration in Cardiac Amyloidosis//Eur Hear. J. 2017. Vol. 38, N 24. P. 1905 - 1908.

278. Крылова Н.С. и др. Гипертрофическая кардиомиопатия и артериальная гипертензия: возможно ли сочетание?//Сердце журнал для практикующих врачей. 2015. Т. 14. N 3(83). С. 164 - 169.

279. Полякова А.А. и др. Гипертрофическая кардиомиопатия в старшей возрастной группе: влияние факторов кардиометаболического риска и полиморфизма гена MADD//Артериальная гипертензия. 2018. Т. 24. N 1. С. 29 - 40.

280. Abel E.D., Litwin S.E., Sweeney G. Cardiac remodeling in obesity//Physiological Reviews. 2008. Vol. 88, N 2. P. 389 - 419.

281. Ommen S.R., Lopez-Jimenez F. Obesity and hypertrophic cardiomyopathy: Chickens, eggs, and causality: Clinical skills remain the key to caring for patients//J. Am. Coll. Cardiol. 2013. Vol. 62, N 5. P. 458 - 459.

282. Olivotto I. et al. Obesity and its association to phenotype and clinical course in hypertrophic cardiomyopathy//J. Am. Coll. Cardiol. 2013. Vol. 62, N 5. P. 449 - 457.

283. Van Straten A.H.M. et al. Increased septum wall thickness in patients undergoing aortic valve replacement predicts worse late survival//Ann. Thorac. Surg. 2012. Vol. 94, N 1. P. 66 - 71.

284. Di Tommaso L. et al. Asymmetric septal hypertrophy in patients with severe aortic stenosis: The usefulness of associated septal myectomy//J. Thorac. Cardiovasc. Surg. 2013. Vol. 145, N 1. P. 171 - 175.

285. Dweck M.R. et al. Left ventricular remodeling and hypertrophy in patients with aortic stenosis: Insights from cardiovascular magnetic resonance//J. Cardiovasc. Magn. Reson. 2012. Vol. 14, N 1. P. 50.

286. Maron B.J., Edwards J.E., Epstein S.E. Disproportionate ventricular septal thickening in patients with systemic hypertension//Chest. 1978. Vol. 73, N 4. P. 466 - 470.

287. Rodrigues J.C.L. et al. Prevalence and Predictors of Asymmetric Hypertensive Heart Disease: Insights From Cardiac and Aortic Function With Cardiovascular Magnetic Resonance//Eur Hear. J Cardiovasc Imaging. 2016. Vol. 17, N 12. P. 1405 - 1413.

288. Tuseth N. et al. Asymmetric septal hypertrophy - A marker of hypertension in aortic stenosis (a SEAS substudy)//Blood Press. 2010. Vol. 19, N 3. P. 140 - 144.

289. Shapiro L.M. et al. An echocardiographic study of localized subaortic hypertrophy//Eur. Heart J. 1986. Vol. 7, N 2. P. 127 - 132.

290. Raissuni Z. et al. Hypertrophic cardiomyopathy mimicking STEMI: The role of cardiac magnetic resonance imaging in the detection of microvascular coronary dysfunction//Diagn. Interv. Imaging. 2014. Vol. 95, N 11. P. 1111 - 1112.

291. Timmer S.A.J., Knaapen P. Coronary Microvascular Function, Myocardial Metabolism, and Energetics in Hypertrophic Cardiomyopathy: Insights From Positron Emission Tomography//Eur Hear. J Cardiovasc Imaging. 2013. Vol. 14, N 2. P. 95 - 101.

292. Zhang Y.D. et al. Hypertrophic cardiomyopathy: Cardiac structural and microvascular abnormalities as evaluated with multi-parametric MRI//Eur. J. Radiol. 2015. Vol. 84, N 8. P. 1480 - 1486.

293. A. et al. Invasive assessment of coronary microvascular dysfunction in hypertrophic cardiomyopathy: The index of microvascular resistance//Cardiovasc. Revascularization Med. 2015. Vol. 16, N 7. P. 426 - 428.

294. Ismail T.F. et al. Coronary microvascular ischemia in hypertrophic cardiomyopathy - A pixel-wise quantitative cardiovascular magnetic resonance perfusion study//J. Cardiovasc. Magn. Reson. 2014. Vol. 16, N 1. P. 49.

295. Olivotto I. et al. Microvascular function is selectively impaired in patients with hypertrophic cardiomyopathy and sarcomere myofilament gene mutations//J. Am. Coll. Cardiol. 2011. Vol. 58, N 8. P. 839 - 848.

296. Zipes D.P. et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death//Circulation. 2006. Vol. 114, N 10. P. e385 - 484.

297. Basavarajaiah S. et al. Prevalence of Hypertrophic Cardiomyopathy in Highly Trained Athletes. Relevance to Pre-Participation Screening//J. Am. Coll. Cardiol. 2008. Vol. 51, N 10. P. 1033 - 1039.

298. Malhotra A., Sharma S. Hypertrophic cardiomyopathy in athletes//Eur. Cardiol. Rev. 2017. Vol. 12, N 2. P. 80 - 82.

299. Pelliccia A. et al. Recommendations for participation in competitive sport and leisure-time physical activity in individuals with cardiomyopathies, myocarditis and pericarditis//Eur. J. Prev. Cardiol. 2006. Vol. 13, N 6. P. 876 - 885.

300. Liebregts M. et al. Validation of the HCM Risk-SCD model in patients with hypertrophic cardiomyopathy following alcohol septal ablation//Europace. 2018. Vol. 20, N FI2. P. 198 - 203.

301. Spoladore R. et al. Pharmacological Treatment Options for Hypertrophic Cardiomyopathy: High Time for Evidence//Eur Hear. J. 2012. Vol. 33, N 14. P. 1724 - 1733.

302. Toshima H. et al. Comparable Effects of Oral Diltiazem and Verapamil in the Treatment of Hypertrophic Cardiomyopathy Double-blind Crossover Study//Jpn. Heart J. 1986. Vol. 27, N 5. P. 701 - 715.

303. Galve E. et al. Late benefits of dual-chamber pacing in obstructive hypertrophic cardiomyopathy: A 10-year follow-up study//Heart. 2010. Vol. 96, N 5. P. 352 - 356.

304. Gentry J.L. et al. Ranolazine for Treatment of Angina or Dyspnea in Hypertrophic Cardiomyopathy Patients (RHYME)//J. Am. Coll. Cardiol. 2016. Vol. 68, N 16. P. 1815 - 1817.

305. Kappenberger L. et al. Pacing in hypertrophic obstructive cardiomyopathy. A randomized crossover study//Eur. Heart J. 1997. Vol. 18, N 8. P. 1249 - 1256.

306. Maron B.J. et al. Assessment of Permanent Dual-Chamber Pacing as a Treatment for Drug-Refractory Symptomatic Patients With Obstructive Hypertrophic Cardiomyopathy//Circulation. 1999. Vol. 99, N 22. P. 2927 - 2933.

307. Maron M.S. et al. Effect of Spironolactone on Myocardial Fibrosis and Other Clinical Variables in Patients with Hypertrophic Cardiomyopathy//Am. J. Med. 2018. Vol. 131, N 7. P. 837 - 841.

308. Nishimura R.A. et al. Dual-chamber pacing for hypertrophic cardiomyopathy: A randomized, double-blind, crossover trial//J. Am. Coll. Cardiol. 1997. Vol. 29, N 2. P. 435 - 441.

309. Olivotto I. et al. Efficacy of Ranolazine in Patients With Symptomatic Hypertrophic Cardiomyopathy: The RESTYLE-HCM Randomized, Double-Blind, Placebo-Controlled Study//Circ. Heart Fail. 2018. Vol. 11, N 1. P. e004124.

310. Slade A.K. et al. DDD pacing in hypertrophic cardiomyopathy: A multicentre clinical experience//Heart. 1996. Vol. 75, N 1. P. 44 - 49.

311. Jung H. et al. Effectiveness and Safety of Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation With Hypertrophic Cardiomyopathy: A Nationwide Cohort Study//Chest. 2019. Vol. 155, N 2. P. 354 - 363.

312. Zhou Y. et al. Non-vitamin K antagonist oral anticoagulants in patients with hypertrophic cardiomyopathy and atrial fibrillation: a systematic review and meta-analysis//J. Thromb. Thrombolysis. 2019. P. doi: 10.1007/s11239-019-02008-3. Epub ahead of print.

313. Rujirachun P. et al. Efficacy and safety of direct oral anticoagulants (DOACs) versus vitamin K antagonist (VKA) among patients with atrial fibrillation and hypertrophic cardiomyopathy: a systematic review and meta-analysis//Acta Cardiol. 2019. P. doi: 10.1080/00015385.2019.1668113. Epub ahead of print.

314. Patten M., Pecha S., Aydin A. Atrial fibrillation in hypertrophic cardiomyopathy: Diagnosis and considerations for management//J. Atr. Fibrillation. 2018. Vol. 10, N 5. P. 1556.

315. Dearani J.A. et al. Surgery Insight: Septal myectomy for obstructive hypertrophic cardiomyopathy - The Mayo Clinic experience//Nat. Clin. Pract. Cardiovasc. Med. 2007. Vol. 4, N 9. P. 503 - 512.

316. Leonardi R.A. et al. Meta-analyses of septal reduction therapies for obstructive hypertrophic cardiomyopathy comparative rates of overall mortality and sudden cardiac death after treatment//Circ. Cardiovasc. Interv. 2010. Vol. 3, N 2. P. 97 - 104.

317. Zeng Z. et al. Comparison of percutaneous transluminal septal myocardial ablation versus septal myectomy for the treatment of patients with hypertrophic obstructive cardiomyopathy-A meta analysis//Int. J. Cardiol. 2006. Vol. 112, N 1. P. 80 - 84.

318. Afanasyev A. V. et al. Single-Centre Experience of Surgical Myectomy for Hypertrophic Obstructive Cardiomyopathy//Hear. Lung Circ. 2019. Vol. 29, N 6. P. 949 - 955.

319. Veselka J. et al. Short- and long-term outcomes of alcohol septal ablation for hypertrophic obstructive cardiomyopathy in patients with mild left ventricular hypertrophy: a propensity score matching analysis//Eur Hear. J. 2019. Vol. 40, N 21. P. 1681 - 1687.

320. Майстренко А.Д. и др. Современное состояние проблемы хирургического лечения гипертрофической обструктивной кардиомиопатии//Вестник хирургии имени И.И. Грекова. 2013. Т. 172. N 2. С. 82 - 87.

321. Хитрова М.Э. и др. Метаанализ результатов хирургического лечения гипертрофической обструктивной кардиомиопатии//Креативная кардиология. 2017. Т. 11. N 4. С. 337 - 347.

322. Богданов Д.В., Шапошник И.И. Варианты клинического течения, исходы и прогноз гипертрофической необструктивной кардиомиопатии - результаты длительного наблюдения//Российский кардиологический журнал. 2019. Т. 24. N 11. С. 48 - 54.

323. Vriesendorp P.A. et al. Validation of the 2014 European Society of Cardiology Guidelines Risk Prediction Model for the Primary Prevention of Sudden Cardiac Death in Hypertrophic Cardiomyopathy//Circ. Arrhythmia Electrophysiol. 2015. Vol. 8, N 4. P. 829 - 835.

324. Falk V. et al. 2017 ESC/EACTS Guidelines for the management of valvular heart disease//Eur. J. Cardiothorac. Surg. 2017. Vol. 52, N 4. P. 616 - 664.

325. Lourenco A.P. et al. An integrative translational approach to study heart failure with preserved ejection fraction: a position paper from the Working Group on Myocardial Function of the European Society of Cardiology//Eur. J. Heart Fail. 2018. Vol. 20, N 2. P. 216 - 227.

326. Мареев В.Ю. и др. Клинические рекомендации ОССН-РКО РНМОТ Сердечная недостаточность: хроническая (ХСН) и острая декомпенсированная (ОДСН). Диагностика, профилактика, лечение//Кардиология. 2018. Т. 58. N 6S. С. 8 - 158.

327. Российское кардиологическое общество. Клинические рекомендации "Артериальная гипертензия у взрослых" [Electronic resource]. 2020. URL: https://scardio.ru/content/Guidelines/Clinic_rek_AG_2020.pdf (accessed: 10.07.2020).

328. Гудкова А.Я., Стрельцова А.А., Костарева А.А. Гипертрофическая кардиомиопатия: современные возможности фармакологических подходов к лечению//Терапевтический архив. 2019. Т. 91. N 9. С. 129 - 136.

329. Ammirati E. et al. Pharmacological treatment of hypertrophic cardiomyopathy: current practice and novel perspectives//Eur. J. Heart Fail. 2016. Vol. 18, N 9. P. 1106 - 1118.

330. Spicer R.L. et al. Hemodynamic effects of verapamil in children and adolescents with hypertrophic cardiomyopathy//Circulation. 1983. Vol. 67, N 2. P. 413 - 420.

331. Flamm M.D., Harrison D.C., Hancock E.W. Muscular subaortic stenosis. Prevention of outflow obstruction with propranolol.//Circulation. 1968. Vol. 38, N 5. P. 846 - 858.

332. Sherrid M.V. Drug Therapy for Hypertrophic Cardiomypathy: Physiology and Practice//Curr. Cardiol. Rev. 2016. Vol. 12, N 1. P. 52 - 65.

333. Sherrid M.V., Gunsburg D., Sharma A. Medical treatment of hypertrophic cardiomyopathy//Curr. Cardiol. Rep. 2000. Vol. 2, N 2. P. 148 - 153.

334. Sherrid M. V. et al. Multicenter study of the efficacy and safety of disopyramide in obstructive hypertrophic cardiomyopathy//J. Am. Coll. Cardiol. 2005. Vol. 45, N 8. P. 1251 - 1258.

335. Sherrid M. V. et al. Treatment of obstructive hypertrophic cardiomyopathy symptoms and gradient resistant to first-line therapy with or verapamil//Circ. Hear. Fail. 2013. Vol. 6, N 4. P. 694 - 702.

336. Adelman A.G. et al. Long-term propranolol therapy in muscular subaortic stenosis.//Br. Heart J. 1970. Vol. 32, N 6. P. 804 - 811.

337. Bonow R.O. et al. Verapamil-induced improvement in left ventricular diastolic filling and increased exercise tolerance in patients with hypertrophic cardiomyopathy: Short- and long-term effects//Circulation. 1985. Vol. 72, N 4. P. 853 - 864.

338. Bonow R.O., Rosing D.R., Epstein S.E. The acute and chronic effects of verapamil on left ventricular function in patients with hypertrophic cardiomyopathy//Eur. Heart J. 1983. Vol. 4, N suppl F. P. 57 - 65.

339. Gistri R. et al. Effect of verapamil on absolute myocardial blood flow in hypertrophic cardiomyopathy//Am. J. Cardiol. 1994. Vol. 74, N 4. P. 363 - 368.

340. Rosing D.R. et al. Verapamil therapy: A new approach to the pharmacologic treatment of hypertrophic cardiomyopathy: III. Effects of long-term administration//Am. J. Cardiol. 1981. Vol. 48, N 3. P. 545 - 553.

341. Rosing D.R. et al. Verapamil therapy: a new approach to the pharmacologic treatment of hypertrophic cardiomyopathy. I. Hemodynamic effects//Circulation. 1979. Vol. 60, N 6. P. 1201 - 1207.

342. Maron B.J. Hypertrophic cardiomyopathy: A systematic review//JAMA 2002. Vol. 287, N 3. P. 1308 - 1320.

343. Said S.M. et al. Transapical approach for apical myectomy and relief of midventricular obstruction in hypertrophic cardiomyopathy//J. Card. Surg. 2012. Vol. 27, N 4. P. 443 - 448.

344. Shah A. et al. Severe symptoms in mid and apical hypertrophic cardiomyopathy//Echocardiography. 2009. Vol. 26, N 8. P. 922 - 933.

345. Maron M.S. et al. Contemporary Natural History and Management of Nonobstructive Hypertrophic Cardiomyopathy//J. Am. Coll. Cardiol. 2016. Vol. 67, N 12. P. 1399 - 1409.

346. McMurray J.J.V. et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart//Eur. Heart J. 2012. Vol. 33, N 14. P. 1787 - 1847.

347. Сафрыгина Ю.В. и др. Сердечные натрийуретические пептиды в плазме больных гипертрофической кардиомиопатией//Кардиология. 2007. Т. 47. N 5. С. 50 - 57.

348. Braunwald E. et al. Idiopathic hypertrophic subaortic stenosis: a description of the disease based upon an analysis of 64 patients//Circulation. 1964. Vol. 30, N 4. P. 3 - 119.

349. Okeie K. et al. Left ventricular systolic dysfunction during exercise and dobutamine stress in patients with hypertrophic cardiomyopathy//J. Am. Coll. Cardiol. 2000. Vol. 36, N 3. P. 856 - 863.

350. Epstein S.E., Rosing D.R. Verapamil: Its potential for causing serious complications in patients with hypertrophic cardiomyopathy//Circulation. 1981. Vol. 64, N 3. P. 437 - 441.

351. Shimada Y.J. et al. Effects of Losartan on Left Ventricular Hypertrophy and Fibrosis in Patients With Nonobstructive Hypertrophic Cardiomyopathy//JACC Hear. Fail. 2013. Vol. 1, N 6. P. 480 - 487.

352. Udelson J.E. et al. Verapamil prevents silent myocardial perfusion abnormalities during exercise in asymptomatic patients with hypertrophic cardiomyopathy//Circulation. 1989. Vol. 79, N 5. P. 1052 - 1060.

353. Wilmshurst P.T. et al. Effects of verapamil on haemodynamic function and myocardial metabolism in patients with hypertrophic cardiomyopathy//Heart. 1986. Vol. 56, N 6. P. 544 - 553.

354. Argulian E. et al. Antihypertensive therapy in hypertrophic cardiomyopathy//Am. J. Cardiol. 2013. Vol. 111, N 7. P. 1040 - 1045.

355. Olivotto I. et al. Patterns of disease progression in hypertrophic cardiomyopathy an individualized approach to clinical staging//Circ. Hear. Fail. 2012. Vol. 5, N 4. P. 535 - 546.

356. Robinson K. et al. Atrial fibrillation in hypertrophie cardiomyopathy: A longitudinal study//J. Am. Coll. Cardiol. 1990. Vol. 15, N 6. P. 1279 - 1285.

357. Olivotto I. et al. Impact of atrial fibrillation on the clinical course of hypertrophic cardiomyopathy//Circulation. 2001. Vol. 104, N 21. P. 2517 - 2524.

358. Maron B.J. et al. Prevalence of hypertrophic cardiomyopathy in a general population of young adults: Echocardiographic analysis of 4111 subjects in the CARDIA study//Circulation. 1995. Vol. 92, N 4. P. 785 - 789.

359. Camm A.J. et al. 2012 focused update of the ESC Guidelines for the management of atrial: Fibrillation An update of the 2010 ESC Guidelines for the management of atrial fibrillation: Developed with the special contribution of the European Heart Rhythm Association//Europace. 2012. Vol. 14, N 10. P. 1385 - 1413.

360. Camm C.F., Camm A.J. Atrial fibrillation and anticoagulation in hypertrophic cardiomyopathy//Arrhythmia Electrophysiol. Rev. 2017. Vol. 6, N 2. P. 63 - 68.

361. Di Cori A. et al. Role of cardiac electronic implantable device in the stratification and management of embolic risk of silent atrial fibrillation: are all atrial fibrillations created equal?//Expert Rev. Cardiovasc. Ther. 2018. Vol. 16, N 3. P. 175 - 181.

362. van Velzen H.G. et al. Incidence of Device-Detected Atrial Fibrillation and Long-Term Outcomes in Patients With Hypertrophic Cardiomyopathy//Am. J. Cardiol. 2017. Vol. 119, N 1. P. 100 - 105.

363. Brambatti M. et al. Temporal relationship between subclinical atrial fibrillation and embolic events//Circulation. 2014. Vol. 129, N 21. P. 2094 - 2099.

364. Camm A.J. et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC)//Eur. Heart J. 2010. Vol. 31, N 19. P. 2369 - 2429.

365. Miller C.A.S. et al. Safety, Side Effects and Relative Efficacy of Medications for Rhythm Control of Atrial Fibrillation in Hypertrophic Cardiomyopathy//Am. J. Cardiol. 2019. Vol. 123, N 11. P. 1859 - 1862.

366. Schaufelberger M. Cardiomyopathy and pregnancy//Heart. 2019. Vol. 105, N 20. P. 1543 - 1551.

367. Azarbal F. et al. Exercise capacity and paroxysmal atrial fibrillation in patients with hypertrophic cardiomyopathy//Heart. 2014. Vol. 100, N 8. P. 624 - 630.

368. Pisters R. et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: The euro heart survey//Chest. 2010. Vol. 138, N 5. P. 1093 - 1100.

369. Lee H.J. et al. Novel Oral Anticoagulants for Primary Stroke Prevention in Hypertrophic Cardiomyopathy Patients with Atrial Fibrillation//Stroke. 2019. Vol. 50, N 9. P. 2582 - 2586.

370. Dominguez F. et al. Direct oral anticoagulants in patients with hypertrophic cardiomyopathy and atrial fibrillation//Int. J. Cardiol. 2017. Vol. 248. P. 232 - 238.

371. Li B. et al. Could direct oral anticoagulants be an alternative to vitamin K antagonists in patients with hypertrophic cardiomyopathy and atrial fibrillation?//Int. J. Cardiol. 2018. Vol. 256. P. 39.

372. Lozier M.R. et al. Thromboembolic outcomes of different anticoagulation strategies for patients with atrial fibrillation in the setting of hypertrophic cardiomyopathy: A systematic review//J. Atr. Fibrillation. 2020. Vol. 12, N 4. P. 2207.

373. Ruff C.T. et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: A meta-analysis of randomised trials//Lancet. 2014. Vol. 383, N 9921. P. 955 - 962.

374. Zhou Y. et al. Non-vitamin K antagonist oral anticoagulants in patients with hypertrophic cardiomyopathy and atrial fibrillation: a systematic review and meta-analysis//J. Thromb. Thrombolysis. 2019. P. doi: 10.1007/s11239-019-02008-3. Epub ahead of print.

375. Connolly S.J. et al. Dabigatran versus warfarin in patients with atrial fibrillation//N. Engl. J. Med. 2009. Vol. 361, N 12. P. 1139 - 1151.

376. A. et al. Dabigatran, Rivaroxaban, or Apixaban versus Warfarin in Patients with Nonvalvular Atrial Fibrillation: A Systematic Review and Meta-Analysis of Subgroups//Thrombosis. 2013. Vol. 2013. Article ID 640723.

377. Бокерия Л.А. и др. Клинические рекомендации "Фибрилляция предсердий". Москва, 2017. 65 с. с.

378. Connolly S.J. et al. Effect of clopidogrel added to aspirin in patients with atrial fibrillation//N. Engl. J. Med. 2009. Vol. 360, N 20. P. 2066 - 2078.

379. Бокерия Л.А. и др. Хирургическое лечение фибрилляции предсердий: современное состояние проблемы//Анналы аритмологии. 2009. Т. 6. N 2. С. 5 - 11.

380. Nishimura R.A., Schaff H.V. Septal myectomy for patients with hypertrophic cardiomyopathy: A new paradigm//J. Thorac. Cardiovasc. Surg. 2016. Vol. 151, N 2. P. 303 - 304.

381. Swistel D.G., Balaram S.K. Surgical Myectomy for Hypertrophic Cardiomyopathy in the 21st Century, the Evolution of the "RPR" Repair: Resection, Plication, and Release//Prog. Cardiovasc. Dis. 2012. Vol. 54, N 6. P. 498 - 502.

382. Swistel D.G., Sherrid M.V. The surgical management of obstructive hypertrophic cardiomyopathy: The RPR procedure-resection, plication, release//Ann. Cardiothorac. Surg. 2017. Vol. 6, N 4. P. 423 - 425.

383. Veselka J. et al. Long-term clinical outcome after alcohol septal ablation for obstructive hypertrophic cardiomyopathy: Results from the Euro-ASA registry//Eur. Heart J. 2016. Vol. 37, N 19. P. 1517 - 1523.

384. Afanasyev A.V. et al. Myectomy Versus Alcohol Septal Ablation in Patients With Hypertrophic Obstructive Cardiomyopathy//Interact. Cardiovasc. Thorac. Surg. 2020. Article number ivaa075. Epub ahead of print.

385. Bogachev-Prokophiev A. et al. Mitral Valve Repair or Replacement in Hypertrophic Obstructive Cardiomyopathy: A Prospective Randomized Study//Interact. Cardiovasc. Thorac. Surg. 2017. Vol. 25, N 3. P. 356 - 362.

386. Bogachev-Prokophiev A. et al. Septal Myectomy With Vs Without Subvalvular Apparatus Intervention in Patients With Hypertrophic Obstructive Cardiomyopathy: A Prospective Randomized Study//Semin. Thorac. Cardiovasc. Surg. 2019. Vol. 31, N 3. P. 424 - 431.

387. Afanasyev A. et al. Myectomy With Mitral Valve Repair Versus Replacement in Adult Patients With Hypertrophic Obstructive Cardiomyopathy: A Systematic Review and Meta-Analysis//Interact. Cardiovasc. Thorac. Surg. 2019. Vol. 28, N 3. P. 465 - 472.

388. Гурщенков А.В. и др. Пятилетний опыт использования мобилизации сердца при септальной миоэктомии//Кардиология и сердечно-сосудистая хирургия. 2018. Т. 11. N 4. С. 54 - 58.

389. Agarwal S. et al. Updated Meta-Analysis of Septal Alcohol Ablation Versus Myectomy for Hypertrophic Cardiomyopathy//J. Am. Coll. Cardiol. 2010. Vol. 55, N 8. P. 823 - 834.

390. Alam M., Dokainish H., Lakkis N.M. Hypertrophic obstructive cardiomyopathy-alcohol septal ablation vs. myectomy: a meta-analysis//Eur. Heart J. 2009. Vol. 30, N 9. P. 1080 - 1087.

391. Swistel D.G., Balaram S.K. Resection, Plication, Release--the RPR Procedure for Obstructive Hypertrophic Cardiomyopathy//Anadolu Kardiyol Derg. 2006. Vol. 6, N Suppl 2. P. 31 - 36.

392. Каштанов М.Г. и др. Этаноловая септальная аблация в лечении обструктивной гипертрофической кардиомиопатии: отбор пациентов и рациональность ее применения//Патология кровообращения и кардиохирургия. 2017. Т. 21. N 1. С. 104 - 116.

393. Batzner A. et al. Hypertrophic obstructive cardiomyopathy-the role of myectomy and percutaneous septal ablation in drug-refractory disease//Dtsch. Aerzteblatt Online. 2019. Vol. 116, N 4. P. 47 - 53.

394. Сухов В.К. и др. Спиртовая септальная абляция при обструктивной гипертрофической кардиомиопатии//Международный журнал интервенционной кардиоангиологии. 2013. N 35. С. 75.

395. Schaff H.V. et al. Expanding the indications for septal myectomy in patients with hypertrophic cardiomyopathy: Results of operation in patients with latent obstruction//J. Thorac. Cardiovasc. Surg. 2012. Vol. 143, N 2. P. 303 - 309.

396. McCully R.B. et al. Extent of clinical improvement after surgical treatment of hypertrophic obstructive cardiomyopathy//Circulation. 1996. Vol. 94, N 3. P. 467 - 471.

397. Orme N.M. et al. Comparison of surgical septal myectomy to medical therapy alone in patients with hypertrophic cardiomyopathy and syncope//Am. J. Cardiol. 2013. Vol. 111, N 3. P. 388 - 392.

398. Halpern D.G. et al. Echocardiography before and after resect-plicate-release surgical myectomy for obstructive hypertrophic cardiomyopathy//J. Am. Soc. Echocardiogr. 2015. Vol. 28, N 11. P. 1318 - 1328.

399. Kaple R.K. et al. Mitral Valve Abnormalities in Hypertrophic Cardiomyopathy: Echocardiographic Features and Surgical Outcomes//Ann. Thorac. Surg. 2008. Vol. 85, N 5. P. 1527 - 1535.

400. Kofflard M.J. et al. Initial results of combined anterior mitral leaflet extension and myectomy in patients with obstructive hypertrophic cardiomyopathy//J. Am. Coll. Cardiol. 1996. Vol. 28, N 1. P. 197 - 202.

401. Schoendube F.A. et al. Long-term clinical and echocardiographic follow-up after surgical correction of hypertrophic obstructive cardiomyopathy with extended myectomy and reconstruction of the subvalvular mitral apparatus//Circulation. 1995. Vol. 92, N 9. P. ii122 - 127.

402. Steggerda R.C. et al. Periprocedural complications and long-term outcome after alcohol septal ablation versus surgical myectomy in hypertrophic obstructive cardiomyopathy a single-center experience//JACC Cardiovasc. Interv. 2014. Vol. 7, N 11. P. 1227 - 1234.

403. Богачев-Прокофьев А.В. и др. Эффективность расширенной миоэктомии у пациентов с желудочковой обструкцией при гипертрофической кардиомиопатии//Кардиология. 2017. Т. 57. N 5. С. 38 - 43.

404. Borisov K.V. Right ventricle myectomy//Ann. Cardiothorac. Surg. 2017. Vol. 6, N 4. P. 402 - 409.

405. Wehman B. et al. Transmitral Septal Myectomy for Hypertrophic Obstructive Cardiomyopathy//Ann. Thorac. Surg. 2018. Vol. 105, N 4. P. 1102 - 1108.

406. Бокерия Л.А., Борисов К.В., Синев А.Ф. Улучшение диастолической функции левого и правого желудочков сердца после хирургической коррекции гипертрофической обструктивной кардиомиопатии при помощи оригинального способа//Грудная и сердечно-сосудистая хирургия. 1999. Т. 4. С. 4 - 10.

407. Бокерия Л.А. Гипертрофическая обструктивная кардиомиопатия//Анналы хирургии. 2013. Т. 5. С. 5 - 14.

408. Takahashi J. et al. Septal Myectomy, Papillary Muscle Resection, and Mitral Valve Replacement for Hypertrophic Obstructive Cardiomyopathy: A Case Report//Ann Thorac Cardiovasc Surg. 2008. Vol. 14, N 4. P. 258 - 262.

409. Cooley D.A., Wukasch D.C., Leachman R.D. Mitral valve replacement for idiopathic hypertrophic subaortic stenosis. Results in 27 patients.//J. Cardiovasc. Surg. 1976. Vol. 17, N 5. P. 380 - 387.

410. Stassano P. et al. Mitral Valve Replacement and Limited Myectomy for Hypertrophic Obstructive Cardiomyopathy: A 25-Year Follow-Up//Texas Hear. Inst. J. 2004. Vol. 31, N 2. P. 137 - 142.

411. Reis R.L. et al. Anterion-superior displacement of papillary muscles producing obstruction and mitral regurgitation in idiopathic hypertrophic subaortic stenosis. Operative relief by posterior-superior realignment of papillary muscles following ventricular septal myectomy//Circulation. 1974. Vol. 50, N 2. P. ii181 - 188.

412. Shimahara Y. et al. Combined mechanical mitral valve replacement and transmitral myectomy for hypertrophic obstructive cardiomyopathy treatment: An experience of over 20 years//J. Cardiol. 2019. Vol. 73, N 4. P. 318 - 325.

413. Topilski I. et al. Long-Term Effects of Dual-Chamber Pacing With Periodic Echocardiographic Evaluation of Optimal Atrioventricular Delay in Patients With Hypertrophic Cardiomyopathy > 50 Years of Age//Am. J. Cardiol. 2006. Vol. 97, N 12. P. 1769 - 1775.

414. Хирманов В.Н. и др. Отдаленные результаты лечения гипертрофической кардиомиопатии с помощью постоянной двукамерной электрокардиостимуляции//Кардиология. 2002. Т. 8. С. 46 - 47.

415. Трешкур Т.В. и др. Внутрисердечная гемодинамика у больных гипертрофической кардиомиопатией при лечении постоянной двукамерной электрокардиостимуляцией//Вестник аритмологии. 1995. Т. 4. С. 248.

416. Daubert C. et al. Pacing for hypertrophic obstructive cardiomyopathy: an update and future directions.//Europace. 2018. Vol. 20, N 6. P. 908 - 920.

417. Quintana E., Cox J.L. Surgical management of atrial fibrillation at the time of septal myectomy//Ann. Cardiothorac. Surg. 2017. Vol. 6, N 4. P. 386 - 393.

418. Бокерия Л.А. и др. Хирургическая коррекция обструктивной гипертрофической кардиомиопатии с SAM-синдромом и фибрилляцией предсердий//Анналы аритмологии. 2016. Т. 13. N 4. С. 216 - 221.

419. Бокерия Л.А. и др. Сочетанная операция миоэктомии межжелудочковой перегородки из правого желудочка и эпикардиальная криомодификация операции "лабиринт"//Анналы аритмологии. 2013. Т. 10. N 2. С. 64 - 68.

420. Bogachev-Prokophiev A.V. et al. Concomitant ablation for atrial fibrillation during septal myectomy in patients with hypertrophic obstructive cardiomyopathy//J. Thorac. Cardiovasc. Surg. 2018. Vol. 155, N 4. P. 1536 - 1542.

421. Monserrat L. et al. Non-sustained ventricular tachycardia in hypertrophic cardiomyopathy: An independent marker of sudden death risk in young patients//J. Am. Coll. Cardiol. 2003. Vol. 42, N 5. P. 873 - 879.

422. Moya A. et al. Guidelines for the diagnosis and management of syncope (version 2009)//Eur. Heart J. 2009. Vol. 30, N 21. P. 2631 - 2671.

423. Sherrid M.V., Massera D. Risk Stratification and Hypertrophic Cardiomyopathy Subtypes//J. Am. Coll. Cardiol. 2019. Vol. 74, N 19. P. 2346 - 2349.

424. Mentias A. et al. Late Gadolinium Enhancement in Patients With Hypertrophic Cardiomyopathy and Preserved Systolic Function//J. Am. Coll. Cardiol. 2018. Vol. 72, N 8. P. 857 - 870.

425. Бельских Л.В. и др. Трансплантация сердца и механическая поддержка кровообращения. Национальные клинические рекомендации. 2016. 115 с. с.

426. Topilsky Y. et al. Left ventricular assist device therapy in patients with restrictive and hypertrophic cardiomyopathy//Circ. Hear. Fail. 2011. Vol. 4, N 3. P. 266 - 275.

427. Biagini E. et al. Heart Transplantation in Hypertrophic Cardiomyopathy//Am. J. Cardiol. 2008. Vol. 101, N 3. P. 387 - 392.

428. Стрюк Р.И. и др. Диагностика и лечение сердечно-сосудистых заболеваний при беременности 2018. Национальные рекомендации//Российский кардиологический журнал. 2018. Т. 3. N 155. С. 91 - 134.

429. Goland S. et al. Pregnancy in women with hypertrophic cardiomyopathy: data from the European Society of Cardiology initiated Registry of Pregnancy and Cardiac disease (ROPAC)//Eur Hear. J. 2017. Vol. 38, N 35. P. 2683 - 2690.

430. Regitz-Zagrosek V. et al. 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy//Eur. Heart J. 2018. Vol. 39, N 34. P. 3165 - 3241.

431. Bowyer L. The Confidential Enquiry into Maternal and Child Health (CEMACH). Saving Mothers' Lives: reviewing maternal deaths to make motherhood safer 2003 - 2005. The Seventh Report of the Confidential Enquiries into Maternal Deaths in the UK//Obstet. Med. 2008. Vol. 1, N 1. P. 54 - 54.

432. Billebeau G. et al. Pregnancy in women with a cardiomyopathy: Outcomes and predictors from a retrospective cohort//Arch. Cardiovasc. Dis. 2018. Vol. 111, N 3. P. 199 - 209.

433. Krul S.P. et al. Systematic Review of Pregnancy in Women With Inherited Cardiomyopathies//Eur J Hear. Fail. 2011. Vol. 13. P. 584 - 594.

434. Tromp C.H.N. et al. Electrical cardioversion during pregnancy: Safe or not?//Netherlands Hear. J. 2011. Vol. 19, N 3. P. 134 - 136.

435. Maron M.S. et al. Prevalence, clinical significance, and natural history of left ventricular apical aneurysms in hypertrophic cardiomyopathy//Circulation. 2008. Vol. 118, N 15. P. 1541 - 1549.

436. Burton H., Alberg C., Stewart A. Heart to Heart: Inherited Cardiovascular Conditions Services - A Needs Assessment and Service Review. 2009. 163 p.

437. Canepa M. et al. Distinguishing ventricular septal bulge versus hypertrophic cardiomyopathy in the elderly//Heart. 2016. Vol. 102, N 14. P. 1087 - 1094.

438. Olesen J.B. et al. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: Nationwide cohort study//BMJ. 2011. Vol. 342, N 7792. P. 320.

439. Lip G.Y.H. et al. Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: The HAS-BLED (hypertension, abnormal renal/liver function, stroke, bleeding history or predisposition, labile INR, elderly, drug//J. Am. Coll. Cardiol. 2011. Vol. 57, N 2. P. 173 - 180.